"I suggest you study the frequency of dose of CSL HAE v Takeda/Shire and the efficacy.
Leon, most of us that follow CSL are interested in the facts. It has been pointed out to you, now twice, that the alternative to the CSL product is massively non-competitive because of the cost penalty. Unless you can come up with some figures to show that CSL is losing market share then nobody will take your posts seriously. Put up some facts or continue look like a down ramper.
The CSL pattern, page-267
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$296.52 |
Change
-0.170(0.06%) |
Mkt cap ! $143.6B | |||
| Open | High | Low | Value | Volume |
| $296.70 | $297.28 | $295.09 | $53.68M | 181.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 20 | $296.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $296.53 | 1296 | 15 |
View Market Depth
| Last trade - 15.00pm 17/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |